PBAC's latest decision on Saxagliptin: Recommended with restriction (2015). Considered for Treatment of patients with type 2 diabetes mellitus in combination with metformin and a sulfonylurea (triple oral therapy).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2010
Submissions
3
2010 → 2015
Eligible population
Adults with type 2 diabetes mellitus inadequately controlled on maximally tolerated doses of metformin and a sulfonylurea, with HbA1c >7% or blood glucose >10 mmol/L in >20% of tests over 2 weeks.
Cost-minimisation analysis; no ICER reported. Submission was assessed on cost-minimisation basis compared to insulin glargine, exenatide, and dapagliflozin.
Submission history
Mar 2010: Recommended with restriction · Authority required (Streamlined)
Jul 2012: Not recommended
Jul 2015: Recommended with restriction · Authority Required